Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels

Yalcin A. D., ÇİLLİ A., Bisgin A., Strauss L. G., Herth F.

EXPERT OPINION ON BIOLOGICAL THERAPY, cilt.13, sa.9, ss.1335-1341, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 9
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1517/14712598.2013.819338
  • Dergi Adı: EXPERT OPINION ON BIOLOGICAL THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1335-1341
  • Anahtar Kelimeler: 25-hydroxyvitamin D, asthma, cardiovascular risk, CXCL8, IL-1 beta, omalizumab, protein C and S deficiency, sCD200, PERSISTENT ALLERGIC-ASTHMA, EXHALED NITRIC-OXIDE, QUALITY-OF-LIFE, ANTI-IGE, IMMUNOGLOBULIN, STRAIL
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: There have been concerns about the cardiovascular safety of omalizumab.